Molecular Diagnostics: Fad or revolution?

Molecular Diagnostics: Tools for medicine

The lightning speed of innovation and technology advances these days makes it hard not only to keep up with the changes in medical technologies, but also to understand which ones are relevant and still be around in the next ten years. Predicting these technology trends is crucial for start-ups, as well as for large biotech and medical device corporations, investors and governments.

As part of our newly launched “MaRS Market Insights” whitepapers series, we decided to take a look at the potential impact that the Molecular Diagnostics (MDx) can have in the delivery of health care, current challenges and the role that Ontario start-ups are playing in this space.

What we learned is that there are tremendous opportunities in using molecular diagnostics for improving the preventive side of health care through better screening, early diagnosis, therapy selection and therapy monitoring. We also had the chance to interview a number of Ontario MDx companies, with great business models, exciting technologies and inspiring visions.

Download the report now

So it is just fad or revolution? We’ll leave it up to you to decide…

Read more and download “Molecular Diagnostics: New tools for evidence-based medicine” here.

Or, see all of our MaRS Reports.

Related Blogs

 

One step closer to better chemo for cancer
Congratulations to MaRS client RNA Diagnostics Inc., winners of the 2010 sanofi pasteur Healthcare and Biotechnology Venture Challenge (HBVC)! Rna Diagnostics’ product target is called RNA Disr

Closer to finding a cure to cancer/New target for cancer therapies
This week, exciting findings outlining a new target for cancer therapies was published in Nature by two independent groups, one in Toronto and one in Italy. They found that the real engines driving

Dx2010: Markers to markets
What’s the future of genetic diagnostics? Where do the commercialization opportunities exist? Now we know. On June 22, the Ontario Genomics Institute and MaRS Future of MedicineTM jointly held

A bright future for diagnostic imaging in Ontario
Advances in diagnostic imaging are helping doctors and radiologists identify malignant tumours, cardiac issues and neurological diseases earlier and more accurately than ever before.  In many cases,

Patient monitoring becomes more friendly with Mespere
Getting your heart checked out just got easier. Waterloo-based med tech start-up Mespere Lifesciences is poised to revolutionize the patient monitoring market. Mespere’s non-invasive central ve

First genetic test for blindness
Next time you head to the eye doctor, you might be sticking out your tongue. MaRS incubator tenant Arctic Dx Inc. just announced a saliva-based genetic test — now available from your eye-care profe

Tags: diagnostics, health care, life sciences